The El Escorial criteria: Strengths and weaknesses

Federica Agosta; Ammar Al-Chalabi; Massimo Filippi; Orla Hardiman; Ryuji Kaji; Vincent Meininger; Imaharu Nakano; Pamela Shaw; Jeremy Shefner; Leonard H. Van Den Berg; Albert Ludolph

doi:10.3109/21678421.2014.964258

The El Escorial criteria: Strengths and weaknesses

Federica Agosta, Ammar Al-Chalabi, Massimo Filippi, Orla Hardiman, Ryuji Kaji, Vincent Meininger, Imaharu Nakano, Pamela Shaw, Jeremy Shefner, Leonard H. Van Den Berg, Albert Ludolph

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

The El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis (ALS) were established 20 years ago and have been used as inclusion criteria for clinical trials. However, concerns have been raised concerning their use as diagnostic criteria in clinical practice. Moreover, as modern genetics have shed new light on the heterogeneity of ALS and the close relationship between ALS and frontotemporal dementia (FTD) recognized, the World Federation of Neurology Research Group on ALS/MND has initiated discussions to amend and update the criteria, while preserving the essential components for clinical trial enrolment purposes.

Original language	English
Pages (from-to)	1-7
Number of pages	7
Journal	Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume	16
Issue number	1-2
DOIs	https://doi.org/10.3109/21678421.2014.964258
Publication status	Published - Mar 1 2015

Keywords

ALS
El Escorial

ASJC Scopus subject areas

Clinical Neurology
Neurology
Medicine(all)

Access to Document

10.3109/21678421.2014.964258

Cite this

@article{98fbdd474a8e4b6ba40c53a7a802b00e,

title = "The El Escorial criteria: Strengths and weaknesses",

abstract = "The El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis (ALS) were established 20 years ago and have been used as inclusion criteria for clinical trials. However, concerns have been raised concerning their use as diagnostic criteria in clinical practice. Moreover, as modern genetics have shed new light on the heterogeneity of ALS and the close relationship between ALS and frontotemporal dementia (FTD) recognized, the World Federation of Neurology Research Group on ALS/MND has initiated discussions to amend and update the criteria, while preserving the essential components for clinical trial enrolment purposes.",

keywords = "ALS, El Escorial",

author = "Federica Agosta and Ammar Al-Chalabi and Massimo Filippi and Orla Hardiman and Ryuji Kaji and Vincent Meininger and Imaharu Nakano and Pamela Shaw and Jeremy Shefner and {Van Den Berg}, {Leonard H.} and Albert Ludolph",

year = "2015",

month = mar,

day = "1",

doi = "10.3109/21678421.2014.964258",

language = "English",

volume = "16",

pages = "1--7",

journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",

issn = "2167-8421",

publisher = "Informa Healthcare",

number = "1-2",

}

TY - JOUR

T1 - The El Escorial criteria

T2 - Strengths and weaknesses

AU - Agosta, Federica

AU - Al-Chalabi, Ammar

AU - Filippi, Massimo

AU - Hardiman, Orla

AU - Kaji, Ryuji

AU - Meininger, Vincent

AU - Nakano, Imaharu

AU - Shaw, Pamela

AU - Shefner, Jeremy

AU - Van Den Berg, Leonard H.

AU - Ludolph, Albert

PY - 2015/3/1

Y1 - 2015/3/1

N2 - The El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis (ALS) were established 20 years ago and have been used as inclusion criteria for clinical trials. However, concerns have been raised concerning their use as diagnostic criteria in clinical practice. Moreover, as modern genetics have shed new light on the heterogeneity of ALS and the close relationship between ALS and frontotemporal dementia (FTD) recognized, the World Federation of Neurology Research Group on ALS/MND has initiated discussions to amend and update the criteria, while preserving the essential components for clinical trial enrolment purposes.

AB - The El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis (ALS) were established 20 years ago and have been used as inclusion criteria for clinical trials. However, concerns have been raised concerning their use as diagnostic criteria in clinical practice. Moreover, as modern genetics have shed new light on the heterogeneity of ALS and the close relationship between ALS and frontotemporal dementia (FTD) recognized, the World Federation of Neurology Research Group on ALS/MND has initiated discussions to amend and update the criteria, while preserving the essential components for clinical trial enrolment purposes.

KW - ALS

KW - El Escorial

UR - http://www.scopus.com/inward/record.url?scp=84925609979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925609979&partnerID=8YFLogxK

U2 - 10.3109/21678421.2014.964258

DO - 10.3109/21678421.2014.964258

M3 - Article

C2 - 25482030

AN - SCOPUS:84925609979

SN - 2167-8421

VL - 16

SP - 1

EP - 7

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

IS - 1-2

ER -

The El Escorial criteria: Strengths and weaknesses

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this